AVE(SH:688067) Zheng Quan Ri Bao Wang·2025-05-23 11:49Core Viewpoint - The company aims to enhance its AI capabilities and product offerings while maintaining a strong focus on technological innovation and efficiency improvements in its operations [1][2]. Group 1: Company Strategy and Innovation - The company is committed to deepening its research in AI and expanding its product matrix, with a focus on technology innovation mechanisms [1]. - The company has accumulated a vast database of desensitized data based on real specimen images, which is a core resource that is difficult for competitors to replicate [2]. - In 2024, the company participated in the development of four group standards and authored four academic works, further solidifying its technological leadership [2]. Group 2: Financial Performance - In a challenging environment for the medical device industry, the company achieved growth in both revenue and net profit in 2024, demonstrating strong operational resilience [2]. - The company implemented cost-reduction and efficiency-enhancement measures across procurement, manufacturing, and R&D, leading to a decrease in product costs [2]. - The sales proportion of high-margin reagents and consumables has gradually increased, resulting in an overall improvement in gross margin compared to the previous year [2]. Group 3: Market Expansion and Product Development - The company has installed its testing instruments in over 6,000 hospitals nationwide, with nearly 8,000 units in use, which supports the growth of high-margin reagent sales [3]. - The company has launched multiple POCT product series covering various health areas, and these products are being sold through various channels including e-commerce platforms and clinics [3]. - The company is actively building third-party IVD laboratories and developing a smart healthcare platform aimed at serving grassroots markets [4].